Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells 367 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 367 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $52.70, for a total value of $19,340.90. Following the transaction, the insider now directly owns 113,620 shares of the company’s stock, valued at $5,987,774. The trade was a 0.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Dennis Cho also recently made the following trade(s):

• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00.
• On Monday, November 4th, Dennis Cho sold 659 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total transaction of $27,388.04.
• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $134,123.84.
• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total value of $10,983.96.

Twist Bioscience Stock Down 3.0 %

Shares of NASDAQ:TWST opened at $47.39 on Friday. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The firm’s 50-day simple moving average is $44.85 and its 200-day simple moving average is $46.60.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB purchased a new position in Twist Bioscience in the 3rd quarter valued at about $34,000. Signaturefd LLC raised its position in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience during the second quarter valued at approximately $43,000. Blue Trust Inc. boosted its position in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in Twist Bioscience in the 2nd quarter valued at $61,000.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research reports. Scotiabank boosted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Barclays lowered their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.